Trial Profile
The effectiveness and safety of certolizumab pegol in clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.
- 20 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2017.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.